New COVID drug candidate passes first safety check in small study
NCT ID NCT07518771
First seen Apr 10, 2026 · Last updated May 19, 2026 · Updated 7 times
Summary
This early-phase study tested the safety of an experimental drug called PA-001 in 47 healthy adults and older volunteers. The goal was to see if the drug is safe and how the body processes it, not to treat COVID-19. Results will help decide the right dose for future patient studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fortrea Clinical Research Unit Inc.
Dallas, Texas, 75230, United States
Conditions
Explore the condition pages connected to this study.